Page 177 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 177
P0330 COST-EFFECTIVENESS ANALYSIS OF HEPATOCELLULAR ePOSTERS
P0331 CARCINOMA SURVEILLANCE IN PATIENTS WITH
P0332 HEPATITIS C RELATED CIRRHOSIS AFTER SUSTAINED
VIROLOGICAL RESPONSE
P0333 Hooman Farhang Zangneh, William W. Wong, Beate Sander,
Chaim M. Bell, Khalid Mumtaz, Matt Kowgier, Adriaan J. Van Der Meer,
Sean P. Cleary, Kelvin Chan, Jordan J. Feld*, Canada
THE ‘GALAD SCORE’ FOR SEROLOGICAL DETECTION
OF HEPATOCELLULAR CARCINOMA: INTERNATIONAL
VALIDATION AND ASSESSMENT OF THE INFLUENCE OF
TUMOUR SIZE AND AETIOLOGY ON MODEL UTILITY
Sarah Berhane*, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada,
Chiaki Kagebayashi, Shinji Satomura, Nora Schweitzer, Arndt Vogel,
Michael Manns, Julia Benckert, Thomas Berg, Jan Best,
Alexander Dechêne, Guido Gerken, Joerg Schlaak, Helen Reeves,
Philip Johnson, The United Kingdom
GENE ALTERATIONS IN TERT PROMOTER, CTNNB1, AND
TP53 ARE CLOSELY ASSOCIATED WITH DEVELOPMENT
AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA:
COMPREHENSIVE ANALYSES BY NEXT GENERATION
SEQUENCING TECHNOLOGY
Yasuhiro Asahina*, Fukiko Kawai-Kitahata, Shun Kaneko,
Hiroko Nagata, Fumio Goto, Satoshi Otani, Miki Taniguchi,
Miyako Murakawa, Sayuri Nitta, Takako Watanabe, Megumi Tasaka-
Fujita,Yuki Nishimura-Sakurai,Yasuhiro Itsui, Mina Nakagawa,
Seishin Azuma, Sei Kakinuma, Shinji Tanaka, Minoru Tanabe,
Nobuyuki Enomoto, Mamoru Watanabe, Japan
AN EPIDEMIOLOGICAL ASSOCIATION BETWEEN THE
TRENDS OF NUCLEOSIDE ANALOGUE PRESCRIPTION
AND LIVER CANCER INCIDENCE FROM 1999 TO 2012 IN
HONG KONG, CHINA
Wai-Kay Seto*, Eric H. Y. Lau, Joseph T. Wu, Ivan Fan-Ngai Hung,
Wai K Leung, James Fung, Ching-Lung Lai, Man-Fung Yuen,
Hong Kong, China
Vienna, Austria • April 22–26, 2015 177
P0331 CARCINOMA SURVEILLANCE IN PATIENTS WITH
P0332 HEPATITIS C RELATED CIRRHOSIS AFTER SUSTAINED
VIROLOGICAL RESPONSE
P0333 Hooman Farhang Zangneh, William W. Wong, Beate Sander,
Chaim M. Bell, Khalid Mumtaz, Matt Kowgier, Adriaan J. Van Der Meer,
Sean P. Cleary, Kelvin Chan, Jordan J. Feld*, Canada
THE ‘GALAD SCORE’ FOR SEROLOGICAL DETECTION
OF HEPATOCELLULAR CARCINOMA: INTERNATIONAL
VALIDATION AND ASSESSMENT OF THE INFLUENCE OF
TUMOUR SIZE AND AETIOLOGY ON MODEL UTILITY
Sarah Berhane*, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada,
Chiaki Kagebayashi, Shinji Satomura, Nora Schweitzer, Arndt Vogel,
Michael Manns, Julia Benckert, Thomas Berg, Jan Best,
Alexander Dechêne, Guido Gerken, Joerg Schlaak, Helen Reeves,
Philip Johnson, The United Kingdom
GENE ALTERATIONS IN TERT PROMOTER, CTNNB1, AND
TP53 ARE CLOSELY ASSOCIATED WITH DEVELOPMENT
AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA:
COMPREHENSIVE ANALYSES BY NEXT GENERATION
SEQUENCING TECHNOLOGY
Yasuhiro Asahina*, Fukiko Kawai-Kitahata, Shun Kaneko,
Hiroko Nagata, Fumio Goto, Satoshi Otani, Miki Taniguchi,
Miyako Murakawa, Sayuri Nitta, Takako Watanabe, Megumi Tasaka-
Fujita,Yuki Nishimura-Sakurai,Yasuhiro Itsui, Mina Nakagawa,
Seishin Azuma, Sei Kakinuma, Shinji Tanaka, Minoru Tanabe,
Nobuyuki Enomoto, Mamoru Watanabe, Japan
AN EPIDEMIOLOGICAL ASSOCIATION BETWEEN THE
TRENDS OF NUCLEOSIDE ANALOGUE PRESCRIPTION
AND LIVER CANCER INCIDENCE FROM 1999 TO 2012 IN
HONG KONG, CHINA
Wai-Kay Seto*, Eric H. Y. Lau, Joseph T. Wu, Ivan Fan-Ngai Hung,
Wai K Leung, James Fung, Ching-Lung Lai, Man-Fung Yuen,
Hong Kong, China
Vienna, Austria • April 22–26, 2015 177
